IRLAB receives grant from The Michael J. Fox Foundation to support development of IRL757 for the treatment of apathy | Placera
Summary
The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms. IRLABs novel approach to treating apathy has the potential to alter an impactful symptom for people affected by Parkinsons both patients and families offering relief where it is currently difficult to find. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinsons patients, business leaders, clinical trial participants, donors, and volunteers. The observed efficacy of IRL757 is thought to be linked to its unique ability to reverse disruption in cortical to sub-cortical nerve signaling, a key factor believed to contribute to apathy in neurological disorders. A clinical trial application (CTA) to start a Phase I study is currently in preparation.IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinsons disease.